The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Chien-Hung Chen, MD
National Taiwan University Hospital
Principal Investigator - David Wang, MD
MegaPro Biomedical Co. Ltd.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chang Gung Medical Foundation
Kaohsiung City, Taiwan
- China Medical University Hospital
Taichung, Taiwan
- Taichung Veterans General Hospital
Taichung, Taiwan
- National Cheng Kung University Hospital
Tainan, Taiwan
- National Taiwan University Hospital
Taipei, Taiwan
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Nov 2018
- Primary completion
- 30 Aug 2020
- Completion
- 30 Oct 2020
- Last update posted
- 22 Oct 2021
- Registered enrollment
- 52
- Registry id
- NCT03407495
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.